Author Archives: Marisa Wexler MS

The European Commission (EC) has approved Blenrep (belantamab mafodotin), a first-in-class therapy developed by GlaxoSmithKline (GSK) for the treatment of multiple myeloma. The approval covers Blenrep as a monotherapy  — that is, without other treatments — in adults who have been treated with at least four…

Darzalex Faspro (daratumumab and hyaluronidase) significantly extended the time people with relapsed or refractory multiple myeloma live without disease worsening, when added to a combination of Pomalyst (pomalidomide) and dexamethasone, a Phase 3 clinical trial shows. Darzalex Faspro is a subcutaneous, or under-the-skin, formulation of…

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Blenrep (belantamab mafodotin-blmf), a first-in-class treatment for heavily pretreated adults with relapsed or refractory multiple myeloma, its developer, GlaxoSmithKline, announced. The approval is specific for people who have been given at least four previous…

The U.S. Food and Drug Administration (FDA) has given Celyad Oncology permission to begin a Phase 1 clinical trial of CYAD-211, an investigational treatment for relapsed or refractory multiple myeloma. The trial is expected to commence by year’s end. “The FDA’s permission to begin the Phase…

A new research project aiming to better understand how fat cells help multiple myeloma cells resist treatment has won a $1.9 million grant from the National Cancer Institute of the National Institutes of Health. The five-year funding was awarded to Michaela Reagan, PhD, a faculty scientist at…

A combination of Sarclisa (isatuximab) plus standard Kyprolis (carfilzomib) and dexamethasone treatment significantly delays disease progression or death in people with relapsed or refractory multiple myeloma, interim results from a Phase 3 clinical trial suggest. The findings were shared at the European Hematology Association (EHA) 2020 Virtual Congress,…

A computer program developed by GNS Healthcare could be used to model and predict disease progression and response to treatment in people with multiple myeloma. Called “Gemini, the in silico ” Patient” (“in silico” refers to analyses done using computer simulation), the program was built through a…

The U.K.’s National Institute for Health and Care Excellence (NICE) has issued a draft “no” statement on the triple combination of Sarclisa (isatuximab), Pomalyst (pomalidomide) and dexamethasone as a treatment for people with relapsed or refractory multiple myeloma. This draft decision means that, at present, NICE will not…

The European Commission (EC) has approved Sanofi‘s Sarclisa (isatuximab), in a triple combination with Pomalyst (pomalidomide) and dexamethasone, to treat adults with relapsed or refractory multiple myeloma. The approval is specifically for those who have tried at least two previous types of treatment, to include…

A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might more effectively treat people with multiple myeloma, a study suggests. Its researchers also report that lowering levels of a particular protein on myeloma cells, MCL-1, may make them more responsive…